HolderBook

Trails Edge Capital Partners, LP

Reported holdings as of Q2 2026, from 3 quarterly filings.

CIK
2077247
Reported value
$629.9M
Positions
35
Top 10 weight
50.3%
Filed
2026-08-14
Days after quarter end
45

Holdings

SecurityTickerValue SharesWeightWeight change Held Change
LB PHARMACEUTICALS INCLBRX$49.4M1,523,0227.85%+0.39pp3q+15.4%+$6.6M
NURIX THERAPEUTICS INCNRIX$38.2M1,573,2206.06%-0.13pp3q-9.8%-$4.1M
IMMUNOCORE HLDGS PLCIMCR$33.8M1,063,2345.36%+0.64pp3q+55.8%+$12.1M
FIRST TRACKS BIOTHERAPEUTICSTRAX$30.5M1,514,0004.84%-newNEW
4D MOLECULAR THERAPEUTICS INFDMT$29.6M2,227,9174.70%+1.93pp2q+71.0%+$12.3M
BIOMARIN PHARMACEUTICAL INCBMRN$29.3M512,0004.65%-newNEW
DESIGN THERAPEUTICS INCDSGN$29.0M2,001,2824.60%+2.52pp2q+134.9%+$16.6M
XENON PHARMACEUTICALS INCXENE$26.6M440,0004.22%-4.31pp3qHELD
MIRUM PHARMACEUTICALS INCMIRM$26.1M223,3124.15%-2.90pp3q-33.0%-$12.9M
INSMED INCINSM$24.6M230,3313.90%-newNEW
CYTOKINETICS INCCYTK$24.5M288,0893.90%-0.63pp2q-4.0%-$1.0M
SYNDAX PHARMACEUTICALS INCSNDX$24.3M1,110,0003.85%+0.10pp2q+58.2%+$8.9M
NEUROGENE INCNGNE$22.5M714,8853.57%-0.05pp3q-8.7%-$2.1M
KAILERA THERAPEUTICS INCKLRA$21.7M984,7863.44%-newNEW
REVOLUTION MEDICINES INCRVMD$21.7M115,7503.44%-2.02pp2q-52.8%-$24.2M
INHIBIKASE THERAPEUTICS INCIKT$18.4M9,051,3182.92%-0.18pp3q+12.3%+$2.0M
INCYTE CORPINCY$17.6M155,0002.79%-newNEW
AVALO THERAPEUTICS INCAVTX$16.5M891,8812.62%-newNEW
MOONLAKE IMMUNOTHERAPEUTICSMLTX$14.6M750,0002.32%-newNEW
FAETH THERAPEUTICS INCFTH$12.9M515,3352.05%+1.14pp2q+312.3%+$9.8M
X4 PHARMACEUTICALS INCXFOR$12.0M2,571,4781.91%-0.53pp3qHELD
OPUS GENETICS INCIRD$11.3M2,743,6581.79%+1.27pp2q+448.7%+$9.2M
SOL-GEL TECHNOLOGIES LTDSLGL$10.3M139,4451.64%+0.09pp2q+63.1%+$4.0M
AURA BIOSCIENCES INCAURA$10.2M1,443,3331.63%-newNEW
CENTURY THERAPEUTICS INCIPSC$10.1M4,134,9691.61%+0.34pp2q+68.8%+$4.1M
INVENTIVA SAIVA$10.0M2,657,9971.60%-1.78pp3qHELD
CAMP4 THERAPEUTICS CORPCAMP$8.4M1,932,9371.34%-0.62pp3qHELD
ALTIMMUNE INCALT$8.1M2,660,0001.28%-newNEW
MINERVA NEUROSCIENCES INCNERV$7.9M1,419,0001.25%-0.71pp2qHELD
PROMIS NEUROSCIENCES INCPMN$7.3M557,1031.16%-0.46pp2qHELD
ONKURE THERAPEUTICS INCOKUR$6.6M1,438,4561.04%-newNEW
FORTE BIOSCIENCES INCFBRX$5.8M273,1810.92%-newNEW
RESEARCH ALLIANCE CORP IIIRACC$5.3M500,0000.85%-newNEW
VTV THERAPEUTICS INCVTVT$3.2M85,1920.51%-0.76pp3q-39.0%-$2.0M
IMAGENEBIO INCIMA$1.7M282,0040.26%-newNEW

By sector

Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.

Biotech & Pharma 90.9%Not classified 9.1%
 
SectorValueShare
Biotech & Pharma$572.4M90.9%
Not classified$57.5M9.1%

Quarter by quarter

QuarterValuePositions NewAddedTrimmed ExitedTop 10 Days to file
Q2 2026$629.9M3513106450.3%45
Q1 2026$436.5M261245965.5%45
Q4 2025$404.7M23000068.5%48

Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.

Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.

Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.